Assessing the potential of DZIP1L gene in autosomal recessive polycystic kidney disease gene therapy
Fahreddin Palaz
Assessing the potential of DZIP1L gene in autosomal recessive polycystic kidney disease gene therapy
AAV / ARPKD / DZIP1L / gene therapy / PKHD1
[1] |
Lu Y, Song Y, Sun S, Zhang L, Chen Y. Gene therapy for pediatric genetic kidney diseases. Pediatr Discov. 2023;1(1):e16.
|
[2] |
Lu H, Galeano MCR, Ott E, et al. Mutations in DZIP1L, which encodes a ciliary-transition-zone protein, cause autosomal recessive polycystic kidney disease. Nat Genet. 2017;49(7):1025-1034.
|
[3] |
Bergmann C, Guay-Woodford LM, Harris PC, Horie S, Peters DJM, Torres VE. Polycystic kidney disease. Nat Rev Dis Prim. 2018;4(1):50.
|
[4] |
Hertz JM, Svenningsen P, Dimke H, et al. Detection of DZIP1L mutations by whole-exome sequencing in consanguineous families with polycystic kidney disease. Pediatr Nephrol. 2022;37(11):2657-2665.
|
[5] |
Cordido A, Vizoso-Gonzalez M, Garcia-Gonzalez MA. Molecular pathophysiology of autosomal recessive polycystic kidney disease. Int J Mol Sci. 2021;22(12):6523.
|
[6] |
Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18(5):358-378.
|
[7] |
Rubin JD, Barry MA. Improving molecular therapy in the kidney. Mol Diagn Ther. 2020;24(4):375-396.
|
[8] |
WareJoncas Z, Campbell JM, Martínez-Gálvez G, et al. Precision gene editing technology and applications in nephrology. Nat Rev Nephrol. 2018;14(11):663-677.
|
/
〈 | 〉 |